

Liver Cirrhosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/LF4276B3DD39EN.html>

Date: March 2022

Pages: 106

Price: US\$ 2,000.00 (Single User License)

ID: LF4276B3DD39EN

Abstracts

Liver Cirrhosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape.

Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and

press releases.

The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 4, 15, 7, 1, 17, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cirrhosis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Liver Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Liver Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Liver Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cirrhosis (Gastrointestinal)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Liver Cirrhosis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Liver Cirrhosis - Overview
Liver Cirrhosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Liver Cirrhosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Liver Cirrhosis - Companies Involved in Therapeutics Development
Alfasigma SpA
Alliancells Bioscience Corporation Ltd
Baylx Inc
Bristol-Myers Squibb Co
Candel Therapeutics Inc
CAR-T (Shanghai) Biotechnology Co Ltd
CellionBioMed Inc
China Immunotech Co Ltd
cStem Regeneration Pharmaceutical Co Ltd
D&D Pharmatech Co Ltd
Elixirgen Therapeutics Inc
Galectin Therapeutics Inc
Galecto Inc
Grifols SA
Gwoxi Stem Cell Applied Technology Co Ltd
Hepion Pharmaceuticals Inc
Innovent Biologics Inc
International Stem Cell Corp
INVENT Pharmaceuticals Inc
Laekna Therapeutics Shanghai Co Ltd
LBL Biotech Corp
Lipocine Inc

Mina Therapeutics Ltd
NGM Biopharmaceuticals Inc
Novo Nordisk AS
Ochre Bio Ltd
Oncocross Co Ltd
Pharmicell Co Ltd
PrimeGen Global Inc
PRISM Pharma Co Ltd
Promethera Biosciences SA
Protgen Ltd
Resolution Therapeutics Ltd
Rohto Pharmaceutical Co Ltd
Shanghai Huicun Medical Technology Co Ltd
Shionogi & Co Ltd
Surrozen Inc
TenNor Therapeutics Ltd
Therabest Co Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
Tuohua Biological Technology Co Ltd
Versantis AG
VESSL Therapeutics Ltd
Xfibra Inc
Liver Cirrhosis - Drug Profiles
7-E - Drug Profile
Product Description
Mechanism Of Action
ademetonine - Drug Profile
Product Description
Mechanism Of Action
ADR-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
albumin (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
albumin (recombinant) - Drug Profile
Product Description

Mechanism Of Action

History of Events

albumin (recombinant) - Drug Profile

Product Description

Mechanism Of Action

History of Events

aldafermin - Drug Profile

Product Description

Mechanism Of Action

History of Events

Antisense RNAi Oligonucleotides for Liver Diseases - Drug Profile

Product Description

Mechanism Of Action

belapectin - Drug Profile

Product Description

Mechanism Of Action

History of Events

BMS-986263 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BXU-004 - Drug Profile

Product Description

Mechanism Of Action

CBMN-1 - Drug Profile

Product Description

Mechanism Of Action

Cell Therapy for Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

Cell Therapy for Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

Cellgram-LC - Drug Profile

Product Description

Mechanism Of Action

History of Events

Cellular Immunotherapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

EBI-02 - Drug Profile

Product Description

Mechanism Of Action

GB-1211 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy for Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate MMP8 for Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate ZSCAN4 for Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene-Modified Cell Therapy for Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

GXHPC-1 - Drug Profile

Product Description

Mechanism Of Action

History of Events

HepaStem - Drug Profile

Product Description

Mechanism Of Action

History of Events

IBI-310 - Drug Profile

Product Description

Mechanism Of Action

History of Events

INV-200 - Drug Profile

Product Description

Mechanism Of Action

LAE-101 - Drug Profile

Product Description

Mechanism Of Action

LPCN-1148 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MTL-CEBPA - Drug Profile

Product Description

Mechanism Of Action

History of Events

OC-101 - Drug Profile

Product Description

Mechanism Of Action

Ozempic - Drug Profile

Product Description

Mechanism Of Action

History of Events

pegbelfermin - Drug Profile

Product Description

Mechanism Of Action

History of Events

PEGXFB-19 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PGGL-1NA - Drug Profile

Product Description

Mechanism Of Action

PGSXCL-1C - Drug Profile

Product Description

Mechanism Of Action

PRI-724 - Drug Profile

Product Description

Mechanism Of Action

History of Events

redasemtide trifluoroacetate - Drug Profile

Product Description

Mechanism Of Action

rencofilstat - Drug Profile

Product Description

Mechanism Of Action

History of Events

rifaximin - Drug Profile

Product Description

Mechanism Of Action

History of Events

Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

Stem Cell Therapy for Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

Stem Cell Therapy for Liver Cirrhosis and Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

Stem Cell Therapy for Pneumonia and Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

SZN-043 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TLY-012 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TNP-2092 - Drug Profile

Product Description

Mechanism Of Action

History of Events

VS-01 - Drug Profile

Product Description

Mechanism Of Action

History of Events

XFB-19 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Liver Cirrhosis - Dormant Projects

Liver Cirrhosis - Discontinued Products

Liver Cirrhosis - Product Development Milestones

Featured News & Press Releases

Dec 22, 2021: Lipocine announces patient dosed in the phase 2 study with LPCN 1148 for management of liver cirrhosis

Nov 15, 2021: Versantis to present positive phase 1b data at AASLD for VS-01 in patients with decompensated Cirrhosis

May 05, 2020: FDA clears LPCN 1148 IND application for phase 2 cirrhosis trial

Dec 11, 2019: The clinical progress of the Great Seal New Drugs has been affirmed and won the first innovative innovation award issued by the Health Policy Association

Nov 20, 2019: Hepion Pharmaceuticals' CRV431 prevents Cirrhosis in experimental model of severe liver disease

Oct 29, 2019: IU School of Medicine researcher awarded \$1.8 million NIH grant for cirrhosis clinical trial

Aug 31, 2019: Versantis: Successful initiation for FiH Study with VS-01

Mar 31, 2019: Versantis: Main patent for VS-01 granted in two additional countries.

Jul 10, 2018: Exalenz Bioscience's Non-Invasive BreathID Test to be Evaluated in Two Bristol-Myers Squibb Phase 2b Clinical Trials in Adult Patients with NASH

Feb 22, 2016: Pharmicell's stem cell therapy from clinical trials (phase 2) is positively effective in treating liver cirrhosis

Mar 25, 2015: NICE recommends treatment for brain condition caused by liver failure

Oct 06, 2014: New Anti-fibrosis Drug with Molecular Targeting DDS Starts Phase-1b Dosing for Cirrhosis Patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Liver Cirrhosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Liver Cirrhosis - Pipeline by Alfasigma SpA, 2022
Liver Cirrhosis - Pipeline by Alliances Bioscience Corporation Ltd, 2022
Liver Cirrhosis - Pipeline by BaylX Inc, 2022
Liver Cirrhosis - Pipeline by Bristol-Myers Squibb Co, 2022
Liver Cirrhosis - Pipeline by Candor Therapeutics Inc, 2022
Liver Cirrhosis - Pipeline by CAR-T (Shanghai) Biotechnology Co Ltd, 2022
Liver Cirrhosis - Pipeline by CellionBioMed Inc, 2022
Liver Cirrhosis - Pipeline by China Immunotech Co Ltd, 2022
Liver Cirrhosis - Pipeline by cStem Regeneration Pharmaceutical Co Ltd, 2022
Liver Cirrhosis - Pipeline by D&D Pharmatech Co Ltd, 2022
Liver Cirrhosis - Pipeline by Elixirgen Therapeutics Inc, 2022
Liver Cirrhosis - Pipeline by Galectin Therapeutics Inc, 2022
Liver Cirrhosis - Pipeline by Galecto Inc, 2022
Liver Cirrhosis - Pipeline by Grifols SA, 2022
Liver Cirrhosis - Pipeline by Gwoxi Stem Cell Applied Technology Co Ltd, 2022
Liver Cirrhosis - Pipeline by Hepion Pharmaceuticals Inc, 2022
Liver Cirrhosis - Pipeline by Innovent Biologics Inc, 2022
Liver Cirrhosis - Pipeline by International Stem Cell Corp, 2022
Liver Cirrhosis - Pipeline by INVENT Pharmaceuticals Inc, 2022
Liver Cirrhosis - Pipeline by Laekna Therapeutics Shanghai Co Ltd, 2022
Liver Cirrhosis - Pipeline by LBL Biotech Corp, 2022
Liver Cirrhosis - Pipeline by Lipocine Inc, 2022
Liver Cirrhosis - Pipeline by Mina Therapeutics Ltd, 2022

Liver Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, 2022
Liver Cirrhosis - Pipeline by Novo Nordisk AS, 2022
Liver Cirrhosis - Pipeline by Ochre Bio Ltd, 2022
Liver Cirrhosis - Pipeline by Oncocross Co Ltd, 2022
Liver Cirrhosis - Pipeline by Pharmicell Co Ltd, 2022
Liver Cirrhosis - Pipeline by PrimeGen Global Inc, 2022
Liver Cirrhosis - Pipeline by PRISM Pharma Co Ltd, 2022
Liver Cirrhosis - Pipeline by Promethera Biosciences SA, 2022
Liver Cirrhosis - Pipeline by Protgen Ltd, 2022
Liver Cirrhosis - Pipeline by Resolution Therapeutics Ltd, 2022
Liver Cirrhosis - Pipeline by Rohto Pharmaceutical Co Ltd, 2022
Liver Cirrhosis - Pipeline by Shanghai Huicun Medical Technology Co Ltd, 2022
Liver Cirrhosis - Pipeline by Shionogi & Co Ltd, 2022
Liver Cirrhosis - Pipeline by Surrozen Inc, 2022
Liver Cirrhosis - Pipeline by TenNor Therapeutics Ltd, 2022
Liver Cirrhosis - Pipeline by Therabest Co Ltd, 2022
Liver Cirrhosis - Pipeline by Tonghua Dongbao Pharmaceutical Co Ltd, 2022
Liver Cirrhosis - Pipeline by Tuohua Biological Technology Co Ltd, 2022
Liver Cirrhosis - Pipeline by Versantis AG, 2022
Liver Cirrhosis - Pipeline by VESSL Therapeutics Ltd, 2022
Liver Cirrhosis - Pipeline by Xfibra Inc, 2022
Liver Cirrhosis - Dormant Projects, 2022
Liver Cirrhosis - Dormant Projects, 2022 (Contd..1)
Liver Cirrhosis - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Liver Cirrhosis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Liver Cirrhosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/LF4276B3DD39EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LF4276B3DD39EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

